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Abstract – Propofol is a common anesthetic, which is 
being investigated as an antidepressant alternative to 
electroconvulsive therapy (ECT). Propofol can induce 
similar EEG effects to that of ECT, and has also 
demonstrated similar improvements in depression 
scores. However, propofol dosing is challenging 
because patients differ in their required drug doses. A 
model of the relationship between administered 
propofol and monitored EEG can be used to improve 
the accuracy and reliability of this treatment. Our 
objective is ultimately to automate processes in 
propofol’s dose determination. A summary of patient-
system modeling in anesthesia will be discussed, along 
with preliminary results from recent open-label trials. 
 
 
I. BACKGROUND 
 
Depression impacts approximately 16.1 million 
US adults [1]. One third of these patients do not respond 
to conventional antidepressants [2]. Electroconvulsive 
therapy (ECT) can offer these patients effective relief [3], 
but its stigmatizing perception can deter many from 
receiving care. ECT’s antidepressant effects have been 
attributed to the induced “burst suppression” [4] – an EEG 
state of alternating quiescence and bursts that can be 
induced by ECT. High concentrations of common 
anesthetics, such as isoflurane and propofol, can also 
induce burst suppression. Both anesthetics have also 
demonstrated antidepressant effects [4,5], along with 
other anesthetics such as nitrous oxide (“laughing gas”) 
[6] and ketamine [7].  
 
 
Figure 1. Burst suppression EEG state induced by isoflurane. EEG-based 
anesthetic depth monitors usually quantify burst suppression by the “ratio” 
between quiescence and bursts over a given epoch. (Kenny 2014) [8] 
 
 
A recent open-label clinical trial at the University 
of Utah [5] investigated propofol’s antidepressant effects, 
in which 6 of 10 subjects met the >50% criteria for 
improvement in their depression scores (HDRS-24), 
while 5 of those 6 met the criteria for remission (HDRS-
24<10). Propofol demonstrated similar antidepressant 
effects to ECT [5] but without the side effects that can be 
associated with ECT, such as amnesia [9].  
 
 
Figure 2. Change in depressive symptoms over a series of 10 treatments of 
propofol-induced burst suppression. (A) Overall changes in HDRS-24 scores, 
(B) HDRS-24 changes scaled to baseline score. (Mickey, Tadler 2018) [5] 
 
If proven effective, propofol might become a 
viable therapeutic alternative for many patients with 
severe depression and limited treatment options. 
Propofol’s neural and antidepressant effects are being 
further studied in a randomized controlled trial (see 
ClinicalTrials.gov: NCT02935647), along with revised 
dosing and administration strategies for propofol.  
 
Propofol-induced burst suppression (PIBS) and 
deep anesthesia has already demonstrated utility in 
clinical practice. By reducing brain metabolism, it offers 
neuroprotection during aneurysm clippings [10], and can 
suppress seizure activity [11]. However, the relationship 
between propofol dose and induced EEG state is 
imprecise, with substantial pharmacokinetic and 
pharmacodynamic inter-individual variability [12] 
 
Thus, accurate and reliable dosing of propofol to 
induce specific levels of burst suppression is challenging. 
 
2 
 
Utah NASA Space Grant Consortium   2018-2019 Update 
II. PK–PD MODELING 
 
The amount of propofol interacting with the 
patient’s brain is a time-sensitive function of how 
propofol accumulates and decays in the body. Thus, 
before relating drug input to EEG response, it is useful to 
determine the drug concentrations over the treatment 
duration. Unlike anesthesia based on inhaled anesthetics, 
the drug concentrations for intravenously delivered 
propofol cannot be monitored in real-time. Population-
based models such as the Schnider pharmacokinetic 
model [13] can be used to estimate propofol 
concentrations, and take into account covariates such as 
age, BMI, and sex.  
 
 
Figure 3. Three-compartment model illustrates the interactions between 
compartments and their associated rate constants. ke0 represents the rate 
constant for equilibration between plasma and effect-site concentrations.  
(Al-Rifai 2016) [14] 
 
The Schnider model uses three compartments 
(central, rapid peripheral, slow peripheral) and a series of 
rate constants. These constants were derived from clinical 
data and govern the overall concentration at the effect-site 
compartment: a conceptual compartment that reflects the 
accumulation of propofol at the response site (presumably 
the brain). Euler’s method was used to implement the 
associated differential equations [15].  
 
The concentration domain is only an intermediate 
domain, which does not yield insight into how patients 
respond to the accumulated propofol. However, it does 
offer a much more convenient representation of the 
temporal implications of the propofol infusion course, 
which is critical to characterize the pharmacodynamic 
response to propofol.  
 
 
 
III. OBJECTIVE 
 
From the open-label trial, we directly observed 
challenges in formalizing, executing, and evaluating the 
PIBS protocol to treat severe depression. Clinicians had 
to “learn” and mentally “map” each patient’s response, 
while relying on human intuition to dose propofol and 
target a burst suppression ratio (BSR) of 80% for 15 
minutes.  Variability was observed between patients and 
their successive treatments, highlighting the need for 
objective, quantitative and individualized guidance for 
dosing.  
To improve the accuracy and reliability achieving 
BSR by PIBS, the utility of pharmacokinetic and 
pharmacodynamic (PK–PD) models will be applied and 
evaluated. 
 
IV. METHODS 
 
Following IRB approval and patient consent, 10 
participants 33.6 ± 9.3 years old and BMI 29.3 ± 5.9 
(mean ± standard deviation), received a series of 10 
treatments of PIBS over the course of 3 weeks, similar to 
a typical treatment series of ECT.  BSR was calculated 
over 1-minute epochs from a left frontal EEG obtained 
using the BIS VISTA Monitoring System (Aspect 
Medical Systems, Norwood, MA) and a 4-electrode 
sensor (BIS Quatro, Covidien, Dublin, Ireland). 
Additional monitoring included EKG, pulse oximetry, 
noninvasive blood pressure, respiratory rate, and end-tidal 
carbon dioxide. 
  
For each treatment, an anesthesiologist 
administered an induction bolus of propofol (2,6-
diisopropylphenol; Diprivan 1% injectable emulsion; 
Fresenius Kabi, Bad Homburg, Germany), along with a 
continuous infusion (Medfusion 3500 Syringe Pump, 
Smiths Medical, Minneapolis, MN) and additional bolus 
doses if needed. Following induction, subjects were 
intubated and ventilated to maintain an end-tidal CO2 of 
35mmHg. 
 
Propofol dosing was guided by real-time EEG 
measurements. Propofol induction doses ranged from 
200–600 mg and continuous infusions ranged from 300–
650 mcg/kg/min. Propofol was dosed to target a BSR of 
80–100% for 15 minutes, similar to a previous protocol 
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studying the antidepressant effects of high-concentration 
isoflurane anesthesia [16].  
 
Beyond clinical judgement and expertise no 
quantitative references or models were used in this 
“manual” approach of propofol dosing.  
 
The recorded propofol infusion courses were 
analyzed by using Schnider pharmacokinetic model to 
estimate predicted effect-site concentrations over the 
course of each subject’s treatment series.  
 
Using MATLAB, the following outlines how 
Euler’s method was applied to simplify the computations 
required in the Schnider model:  
  
x1 = 0; %initial mass in central compartment 
Cp = [0]; %initial plasma concentration 
Ce = [0]; %initial effect-site concentration 
 
step = 0.1 %minutes 
 
for n = 1:length(t) %loop over desired duration of simulation 
dx1 = [x2*k21 + x3*k31 x1*(k10+k12+k13)]*step + B(n); %central 
dx2 = [x1*k12 - x2*k21]*step; %rapid peripheral 
dx3 = [x1*k13 - x3*k31]*step; %slow peripheral  
dCe = [keo*(Cp - Ce)]*step;  %effect-site 
 
nCp = x1/V1; %next Cp 
nCe = Ce + dCe; %next Ce 
 
Cp = [Cp nCp]; %updated Cp vector 
Ce = [Ce nCe]; %updated Ce vector 
end  
 
V. RESULTS 
 
Figures 4 through 9 show an example of the 
pharmacokinetic and pharmacodynamic analysis and 
modeling of one of the subject’s (ID: PROP03) ninth 
treatment from the open-label trial. Figure 5 offers further 
perspective into how PROP03 compared with other 
female subjects, as well as inter-treatment variability in 
propofol concentrations.  
 
Pharmacokinetics  
 
 During the ninth treatment, PROP03 required 4 
boluses of propofol to satisfy the treatment protocol’s 
BSR range, as well as a continuous infusion of 600 
mcg/kg/min.  
 
 
Figure 4. Pharmacokinetics of a subject’s 9th treatment. TOP: the predicted 
effect-site concentrations determined by the Schnider model, derived from an 
infusion time course. BOTTOM: both bolus doses and a 600 mcg/kg/min 
propofol infusion can together be represented in time by their drug input rates 
over time. The concentration domain (red) accounts for the temporal aspect of 
drug dosing. 
 
Beyond changes in concentration over each 
treatment domain, concentration differences between the 
treatments and between the patients were also analyzed. 
Given the rapid changes in concentration during 
induction, the 10-minutes prior to ending propofol 
administration were analyzed to more closely reflect 
steady state concentrations. Female subjects (n = 5) and 
each of their first nine treatments were examined because 
of a wider and more evenly distribution of BMI (30.0 ± 
7.5kg m-2) compared to male subjects (28.7 ± 4.7kg m-2). 
 
Figure 5 illustrates our findings and suggests a 
correlation with required propofol concentrations to 
satisfy the target BSR range and BMI of the subject, given 
that the subjects are ordered by increasing BMI, as listed: 
PROP04 = 19.4 kg m-2, PROP03 = 25.1 kg m-2, PROP09 
= 33.4 kg m-2, PROP02 = 34.2 kg m-2, PROP07 = 37.8 kg 
m-2. 
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Figure 5. Female subjects (ranked from left to right by increasing weight) 
varied widely in their average propofol concentrations to satisfy the desired 
BSR range, according to the Schnider model. Average propofol concentrations 
were calculated over the 10 minutes before the propofol infusion was stopped. 
The boxplot highlights both inter-patient variability and inter-treatment 
variabilities in the concentration domain.  
 
Pharmacodynamics 
 
 Pharmacodynamic modeling seeks to relate the 
estimated concentrations to the monitored effect, in our 
case: the BSR output reported by the BIS Monitor (one-
minute averages), which is shown in Figure 6. Upon the 
initial bolus of propofol, BSR rapidly increases as brain 
activity becomes suppressed, and rapidly decreases as 
brain activity recovers and propofol is eliminated from the 
subject’s body.  
 
 Figure 7 illustrates the relationship of a 
pharmacodynamic model of PROP03’s ninth treatment.  
 
 
 
 
 
 
 
Figure 6. The corresponding monitored BSR output for PROP03’s 9th 
treatment of propofol. Given experience from the previous 8 treatments to 
gauge the subject’s response and sensitivity to propofol, the target BSR range 
(80-100% for 25 minutes) was well satisfied by the anesthesiologist. 
 
 
 
 
 
Figure 7. BSR outputs by the BIS Monitor are plotted against the estimated 
effect-site concentrations, derived from the infusion data. The data was fit 
according to a sigmoidal curve, with Hill and EC50 coefficients of 13 and 12.5 
(mcg/mL). Over the duration of the treatment, the plot’s general trend is to 
circulate counter-clockwise toward returning to lower concentrations, during 
emergence and recovery.  
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VI. DISCUSSION 
 
As a retrospective analysis of data that was originally not 
collected with a pharmacokinetic/pharmacodynamic 
analysis in mind, the conclusiveness of the results is 
limited in a number of ways. 
 
 Time synchronization: Although updated drug 
inputs (see Figure 4) and EEG outputs (see Figure 5) have 
been gathered for all patients (n = 10) and all treatments 
(m = 99), synchronizing the clocks between the BIS 
monitor and clinical administration of propofol was not 
adequately conducted, nor was a major research priority. 
Assumptions were required to force-fit potential models 
of how BSR related to predicted effect-site 
concentrations.  
 
 Time resolution is another factor that required 
assumptions parameterizing the PK–PD models. The 
bolus and infusion data were recorded in minute intervals, 
while only the averaged BSR could be exported every 
minute. Assumptions had to be made about how long each 
bolus was administered for, and that they were 
administered at the beginning of each minute interval.  
 
 A common consequence that can occur from poor 
time synchronization and resolution is hysteresis: a 
phenomenon in which a clinical response (e.g. BSR) 
depends on its past trend of propofol concentration 
changes, yielding multiple effects associated with the 
same propofol concentration.  
 
 Notably, hysteresis can also result from a ke0 
pharmacokinetic parameter that is not optimized for the 
individual patient. Once the time synchronization and 
time resolution has been eliminated as a source of the 
hysteresis loop, optimizing the ke0 constant, i.e., the 
estimated “time to peak effect” (see Figure 8) for its 
effect-site compartment, is a way to collapse a hysteresis 
loop (see Figure 9) and estimate the patient-
individualized ke0 parameter.  
 
 
Figure 8. Plot of multiple predicted effect-site concentrations with different 
ke0s (Schnider in red, Sepúlveda in green, and Marsh original in blue). Altering 
the ke0 value of a pharmacokinetic model will alter the rates of accumulation 
and decay in the effect-site compartment. This directly relates to changes in the 
“time to peak effect” and alignment in the eventual pharmacodynamic model. 
(Sepulveda 2018) [17] 
 
 
 
Figure 9. Upon adjusting the ke0 value from 0.456 min-1 (value determined 
by Schnider) to 0.1 min-1 (suggests longer time to peak effect), the plot’s 
hysteresis loop visually collapses. Compare with Figure 6. This difference can 
offer much utility in future PK–PD of subjects.  
 
Significance 
  
Improving the accuracy and reproducibility of 
this propofol-based antidepressant therapy will directly 
reduce potential confounding variables impacting the 
clinical effect of propofol. As reported by Mickey, Tadler, 
et al. [5], subjects experienced a variety of   degrees and 
durations of burst suppression. Subjects receiving lower 
degrees and duration of burst suppression within the 80-
100% BSR range tended to demonstrate greater 
improvements in their depression scores [5]. Over the 10-
treatment series, different clinicians administered the 
treatment, with presumably different approaches to 
dosing. Standardizing the control of patient EEG 
dynamics through individualized PK-PD models might 
reduce the impact of these factors.  
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Given the treatment’s high propofol doses, safety 
is also an important concern. Individualized PK-PD 
modeling might help guide clinicians to identify the 
necessary doses and timing in a quantitative fashion. This 
also includes when and how to step down and taper the 
propofol infusion to achieve a desired time of PIBS.  
 
Closed-loop control advances in anesthesiology 
can benefit space mission personnel through more 
independent and technological means of clinical care, 
where expertise may be limited. For example, without a 
formally trained anesthesiologist, an automated total 
intravenous anesthesia (TIVA) device can still help 
provide treatment options.   
 
Follow-on Clinical Trial  
 
The missing link to pharmacodynamically model 
subjects from the open-label trial was synchronized time. 
In a follow-up randomized controlled trial, we seek to 
align the BIS Monitor’s clock with the room clock and 
align the drug input with the EEG outputs. Furthermore, 
we seek to successively build upon our pharmacodynamic 
models after each treatment to improve how we target 
BSR in the following treatment. The predicted 
concentrations associated with the desired BSR range will 
be pursued through updated dosing strategies. 
 
Given quantitative guidance from our models, we 
hypothesize that 1) BSR accuracy will improve over 
successive treatments, and 2) the pharmacodynamics of 
each subject is constant over the treatment series. We can 
objectively evaluate the pharmacodynamics between the 
treatments by comparing their pharmacodynamic 
parameters. Moreover, we can further overcome 
hysteresis by developing a standard algorithm to collapse 
and minimize hysteresis loops. 
 
The collection and processing of clinical data will 
not only be used to develop patient-models, but also help 
develop an automated controller to further compare those 
models with real-time EEG-BSR feedback, then 
objectively recommend changes in how propofol is 
administered to reduce error from the ideal BSR target. 
This controller will be evaluated by simulation, and 
potentially in the clinical setting.  
 
More updates will be shared once the blinded 
study has concluded and proper due diligence has been 
conducted.  
 
VII. FUTURE WORK 
 
Extensive literature on PK–PD modeling exists 
and can be directly applied to a follow-up trial 
investigating propofol’s neural and antidepressant effects. 
Adaptively modeling the patient-individualized 
relationship between drug input and BSR output may 
allow improved dosing to better target the desired EEG 
response. This would allow to augment the clinician’s 
intuition by providing a model-based tool to individualize 
propofol dosing.  
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